错误部

The Lancet Pub Date : 2025-10-09 DOI:10.1016/s0140-6736(25)02058-6

{"title":"错误部","authors":"","doi":"10.1016/s0140-6736(25)02058-6","DOIUrl":null,"url":null,"abstract":"Rossignol P, Zannad F, Massy Z, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 2025; 406: 705–18—In this Article, the spelling of author Delphine Maucort-Boulch's name was incorrect. This correction has been made to the online version as of Oct 9, 2025.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"590 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Department of Error\",\"authors\":\"\",\"doi\":\"10.1016/s0140-6736(25)02058-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rossignol P, Zannad F, Massy Z, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 2025; 406: 705–18—In this Article, the spelling of author Delphine Maucort-Boulch's name was incorrect. This correction has been made to the online version as of Oct 9, 2025.\",\"PeriodicalId\":22898,\"journal\":{\"name\":\"The Lancet\",\"volume\":\"590 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0140-6736(25)02058-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)02058-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

罗晓峰，陈建军，陈建军，等。慢性血液透析高危心血管不良结局患者服用螺内酯（ALCHEMIST）：一项多中心、双盲、随机、安慰剂对照试验和最新荟萃分析《柳叶刀》2025年;[06:705 . 18]在这篇文章中，作者Delphine Maucort-Boulch的名字拼写错误。此更正已于2025年10月9日对在线版本进行了修改。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Department of Error

Rossignol P, Zannad F, Massy Z, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 2025; 406: 705–18—In this Article, the spelling of author Delphine Maucort-Boulch's name was incorrect. This correction has been made to the online version as of Oct 9, 2025.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet

自引率

0.00%

发文量